Coegin Pharma is a Nordic biotech company dedicated to the development of innovative therapies for cancer and kidney diseases, where there is a great medical need for novel treatments and pharmaceuticals.

Coegin Pharma is developing a new generation of therapeutics based on decades of research into the unique target enzyme cPLA₂α. The enzyme has proved to play a central role in a number of inflammation-driven cancers and chronic kidney diseases.

Media contact

Tore Duvold CEO
+45 61 90 50 66
[email protected]